In conclusion, our preliminary data suggest that the oncogenic mutations of PIM1 and MYD88 in our DLBCL cohort may improve the diagnosis and prognosis of DLBCL patients in an advanced stage. The gene discussed is MYD88; the disease is diffuse large B-cell lymphoma.